Tenvie Therapeutics

Tenvie Therapeutics is a biotechnology company dedicated to designing small molecules that transform the treatment of neurological disorders. The company’s foundation is purpose-built, with a diversified portfolio of small molecule products and an experienced CNS drug development team to rapidly deliver multiple clinical assets. Tenvie is advancing a therapeutic pipeline focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its wholly owned, highly brain-penetrant, and precisely designed peripherally restricted small molecule portfolio addresses three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with other programs in preclinical development.